WANG HUIMIN 4
4 · Edwards Lifesciences Corp · Filed May 10, 2022
Insider Transaction Report
Form 4
WANG HUIMIN
CVP, Japan & Intercontinental
Transactions
- Tax Payment
Common Stock
2022-05-08$100.52/sh−4,210$423,189→ 100,299.802 total - Exercise/Conversion
Common Stock
2022-05-08+6,956→ 104,509.802 total - Sale
Common Stock
2022-05-09$98.71/sh−3,675$362,759→ 100,299.802 total - Tax Payment
Common Stock
2022-05-07$100.52/sh−363$36,489→ 97,553.802 total - Exercise/Conversion
Common Stock
2022-05-09$35.20/sh+3,675$129,348→ 103,974.802 total - Exercise/Conversion
Performance Rights
2022-05-08−6,956→ 0 totalFrom: 2022-05-08Exp: 2026-05-07→ Common Stock (6,956 underlying) - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2022-05-09−3,675→ 33,075 totalExercise: $35.20From: 2016-06-12Exp: 2023-05-11→ Common Stock (3,675 underlying)
Footnotes (2)
- [F1]On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.
- [F2]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2022.